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Microchamber Cultures of 
Bladder Cancer: A Platform 
for Characterizing Drug 
Responsiveness and Resistance in 
PDX and Primary Cancer Cells
Pantea Gheibi1, Shuxiong Zeng2, Kyung Jin Son1, Tam Vu1,3, Ai-Hong Ma4, Marc A. Dall’Era5, 
Stanley Alexander Yap5, Ralph W. de Vere White5, Chong-Xian Pan2,5 & Alexander Revzin1,6
Precision cancer medicine seeks to target the underlying genetic alterations of cancer; however, it has 
been challenging to use genetic profiles of individual patients in identifying the most appropriate anti-
cancer drugs. This spurred the development of patient avatars; for example, patient-derived xenografts 
(PDXs) established in mice and used for drug exposure studies. However, PDXs are associated with 
high cost, long development time and low efficiency of engraftment. Herein we explored the use 
of microfluidic devices or microchambers as simple and low-cost means of maintaining bladder 
cancer cells over extended periods of times in order to study patterns of drug responsiveness and 
resistance. When placed into 75 µm tall microfluidic chambers, cancer cells grew as ellipsoids reaching 
millimeter-scale dimeters over the course of 30 days in culture. We cultured three PDX and three clinical 
patient specimens with 100% success rate. The turn-around time for a typical efficacy study using 
microchambers was less than 10 days. Importantly, PDX-derived ellipsoids in microchambers retained 
patterns of drug responsiveness and resistance observed in PDX mice and also exhibited in vivo-like 
heterogeneity of tumor responses. Overall, this study establishes microfluidic cultures of difficult-to-
maintain primary cancer cells as a useful tool for precision cancer medicine.
Cancer remains a significant source of morbidity and mortality worldwide1. Traditionally, cancer treatment is 
designed based on the anatomical location and stage without considering the underlying cancer and individual 
patient variations. For example, all stage IV non-small cell lung cancers (NSCLC) are treated with platinum-based 
doublets while metastatic bladder cancer is usually treated with GC (gemcitabine and cisplatin/carboplatin) or 
MVAC (methotrexate, vinblastine, doxorubicin/adriamycin and cisplatin)2. Recent developments and clini-
cal applications in “-omics” technologies brought forth the concept of precision cancer medicine which aims 
to individualize therapy based on the underlying molecular characteristics of cancer in specific patients. With 
the advance in omics technologies, a seemingly “uniform” cancer may be classified into several sub-groups and 
treated based on the underlying molecular and genomic alterations. For example, lung adenocarcinoma can be 
classified and treated based on EGFR activating mutation, EML4-ALK translocation and other genetic alterations. 
In fact, targeted therapy matched against these genetic alterations achieves a response rate of over 70%3–5, com-
pared to less than 30% with non-specific platinum-based doublet chemotherapy2. Another success story for the 
field of precision cancer medicine is targeting of B-RAF mutation in melanoma6,7.
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While these success stories are encouraging, the vast majority of cancer patients continue to be treated using 
“one-formula-fits-all” approach. A major reason for this is that each cancer harbors multiple genetic alterations, 
from a few in pediatric cancers to dozens and hundreds in adult cancers8, and computational biology tools are not 
able to distinguish the driver mutations from passenger mutations that have little impact on cancer function. Even 
in those patients whose cancers respond to targeted therapy, secondary resistance commonly develops within 
a few months. Biopsies of the resistant tumors have been used to study resistance mechanisms; however, small 
numbers of cells and impracticality of serial biopsies hinder the study of secondary resistance.
To address the unmet needs of precision cancer medicine, various cancer models have been established. One 
of the most commonly used in vivo models is patient derived xenografts (PDXs)9,10 which are developed from 
uncultured patient cancer cells. Human cancer cells have been engrafted into immunodeficient mice to create 
PDX models of pancreatic cancer, hepatocellular carcinoma, breast cancer, prostate cancer and many other cancer 
types11–14. Our team has a long-standing interest in bladder cancer and has recently reported the development 
of 22 PDX mice that could be used for drug screening purposes15. While extremely valuable, PDX models have 
disadvantages, such as long engraftment time (up to 6 months), low engraftment rate and high cost.
To address the drawbacks of in vivo models, several in vitro models have been developed with the goal to 
maintain phenotype of primary cancer cells long enough to evaluate cancer drug responsiveness and resist-
ance16–20. These in vitro cultures aim to recapitulate aspects of tumor microenvironment including three dimen-
sionality, heterotypic interactions and mechanical properties. 3D or spheroid cultures have proven particularly 
popular for drug screening and cancer biology studies21–24. Methods for forming spheroids have included hanging 
drops25, arrays of pyramidal wells26, microfluidic hydrodynamic traps27 and gel embedding28. However, there 
remains a need for new methods to maintain primary cancer cells in vitro.
Our team has recently described the use of pump-less microfluidic channels or microchambers for culturing 
primary hepatocytes and stem cells29,30. Here we investigated utility of microchambers for long-term maintenance 
of primary cancer cells which represents an important unmet need for the field of precision cancer medicine. As 
shown in Fig. 1A, our devices were simple microfluidic chambers with cloning cylinders serving as media reser-
voirs. Because the roof of microchambers was composed of oxygen-permeable silicone rubber, cancer constructs 
remained uniformly oxygenated and uniformly epithelial even when reaching millimeter lateral dimensions over 
30 days in culture. Successful cultivation of bladder cancer cells from PDX mice as well as from patient cancer 
specimens was demonstrated. Beyond long term maintenance, we demonstrated that microchamber cultures 
from specific PDX models retained patterns of drug responsiveness and resistance observed in mice. This proof 
of concept study moves us closer to a microfluidics-based platform for long-term cultivation of cancer cells and 
screening of anti-cancer drugs.
Results and Discussion
Spatial confinement of bladder cancer spheroids in microchambers. We have previously observed 
that difficult-to-culture primary epithelial cells (hepatocytes) were maintained in microfluidic devices without 
perfusion for up to three weeks with minimal loss of phenotype or function30. Herein we wanted to explore the 
use of microchambers for cultivation of cancer cells. A typical microchamber used in this study is shown in 
Fig. 1A, with dimensions provided in Figure S1. Soft lithography was used to pattern transport channels and a cell 
culture chamber in polydimethyl siloxane (PDMS) – gas permeable silicone rubber. This PDMS top was reversi-
bly bonded onto a glass coverslip and was outfitted with cloning cylinders serving as media reservoirs. Much like 
a regular culture dish, media exchange was accomplished by aspirating and refilling the reservoirs.
Our initial efforts to culture single cell suspension of bladder cancer cells were only moderately successful. To 
enhance survival and maintenance of cancer cells, we explored a strategy of forming multi-cellular clumps prior 
to seeding into microchambers16. Cancer tissue was carefully dissociated into cell clusters using collagenase type-I 
solution and separated using 40-µm cell strainer and 180-µm nylon mesh (Figure S2). Cell clusters captured in 
the strainer were cultured in 12-well plates (see Methods section for details) and, after 24 h, were seeded into 
microchambers. Typically, ~1 cm3 piece of tumor tissue yielded enough cell clumps to seed ~20 microchambers 
(1–20 clumps per device).
First, we characterized growth for bladder cancer cells in microchambers and Matrigel cultures. For these 
comparison studies, we used bladder cancer PDX BL0269 - developed from an invasive (advanced) bladder 
cancer15. As highlighted by a cartoon in Fig. 1A, the constructs growing in microchambers resembled ellip-
soids and not spheroids, with z-axis defined by the 75 µm height of the microchamber. Growth was evaluated by 
measuring changes in volume using bright-field microscope and image analysis. Figure S3 highlights similari-
ties in growth for both systems, suggesting that our microchamber cultures were comparable to the established 
Matrigel-based culture system. 3D bladder cancer constructs growing in microchambers stained strongly for 
cytokeratin and exhibited localization of F -actin to cell-cell junctions, suggesting maintenance of epithelial phe-
notype in (Fig. 1B). In addition to BL0269, we demonstrated maintenance of cells from BL0440 and BL0382 PDX 
mice (Figure S4). These three PDX models differed in patient age, cancer stage, drug resistance profile and prior 
exposure to chemotherapy15, suggesting that microchamber ellipsoid cultures were of general utility for mainte-
nance of bladder cancer cells.
We should note that floating spheroids were also utilized as controls in our early experiments. However, we 
found this culture format to be suboptimal for monitoring changes in spheroid size over time and have focused on 
Matrigel-embedment of spheroids as a culture method to compare against our microfluidic cultures.
Cancer ellipsoids may be cultured in microchambers without passaging for over 30 
days. Tumors can grow in mice over a period of several weeks during which responsiveness and resistance to 
anti-cancer drugs may be studied. On the other hand, cancer spheroids cultured in suspension or in Matrigel slow 
down growth after two weeks in culture and develop necrotic cores when diameters exceed 400 µm16,21. While 
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suitable for some drug screening applications, this timeframe may be insufficient for studies focusing on how 
anti-cancer drug resistance develops and whether salvage drug or drug combinations can overcome resistance. 
Unlike standard spheroid culture methods, the growth rate of cancer constructs in microchambers remained 
unchanged over 30 days of culture and there was no necrosis in the middle of ellipsoid tumor mass (Fig. 1C,D). 
The lack of necrotic core may be explained by the ellipsoid geometry of cancer constructs that allows for sufficient 
nutrient delivery and by the fact that the roof of the microchamber is composed of silicone rubber – an oxygen 
permeable material. The latter property of our culture system ensures uniform oxygen delivery regardless of the 
lateral dimensions, as highlighted by cartoon in Fig. 2A. Modeling of oxygen levels in the core of 400 µm diame-
ter spheroids in suspension culture vs. ellipsoids in microchambers highlights the differences in oxygen tension 
between the two systems (see Fig. 2B and supplemental materials for details of COMSOL modeling). Interestingly, 
as shown in Fig. 2C, we observed differences in localization of Ki67-expressing proliferating cells depending on 
the size of ellipsoids. While proliferating cells were uniformly distributed throughout smaller ellipsoids (<150 µm 
diameter), these cells were confined to the periphery of larger constructs. A number of previous reports suggested 
hypoxia as the possible inducer of dormancy in cells located at the core of cancer spheroids16,21,31,32. Given suffi-
cient oxygen delivery, differences in location of dormant and proliferating cells within ellipsoids of different sizes 
may be attributed to other, yet to be determined mechanisms.
Drug responses of cancer ellipsoids parallel those observed in PDX mice. An important goal of 
this study was to compare drug responses of bladder PDX models in vivo and in microchamber cultures. We 
chose BL0269 PDX to carry out this comparison because this bladder cancer model had an interesting pattern of 
drug responsiveness15. It was relatively resistant to cisplatin and gemcitabine, two chemotherapy drugs commonly 
used for treatment of bladder cancer. However, BL0269 was found to harbor a PI3K H1047R activation mutation 
and was sensitive to a targeted therapeutic agent GDC-0941 – a small molecule inhibitor of PI3K.
Figure 1. Bladder cancer cultures in microfluidic devices. (A) Top: depiction of ellipsoid cancer constructs 
in microchambers. Bottom: an image of a representative microchamber. (B) F-actin and cytokeratin 
staining demonstrates that bladder cancer ellipsoids retain epithelial phenotype after 10 days of culture in 
microchambers. Nuclei are stained with DAPI (Blue). (C) Bright field images showing growth of cancer 
ellipsoids in microchambers. (D) Growth of ellipsoids from BL0269 over 30 days in microchambers. Scale bars 
100 μm.
www.nature.com/scientificreports/
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We cultured BL0269 cells in microchambers for 10 days to allow ellipsoids to exceed 100 µm diameters and 
then challenged cultures with anti-cancer drugs for the additional 6 days. As seen from Fig. 3(A and B), BL0269 
ellipsoids were almost unchanged after 48 h exposure to 10 µM cisplatin or 10 µM gemcitabine, but shrunk to half 
the size in response to 1 µM GDC-0941. The concentrations were chosen based on reports of efficacy of these 
drugs both in vivo and in vitro33–38.
As seen from Fig. 3B, the pattern of responsiveness and resistance in microchamber cultures was very similar 
to our previous observations with PDX in NSG mice15. BL0269 was relatively resistant to cisplatin and gemcit-
abine single agents. The cisplatin/gemcitabine combination was slightly more effective than single agents. Because 
this tumor culture harbors a PI3K activation mutation, it was very sensitive to GDC-0941. The combination of 
three drugs was more effective than GDC-0941.
Another important experiment was carried out with BL0269 tumors that were resistant to GDC-0941. We 
noticed that, while daily treatment of PDX BL0269 mice with GDC-0941 caused tumor size to decrease initially, 
tumors became resistant over subsequent 20 days of treatment and began to increase in volume (unpublished 
data). These resistant BL0269 tumors were excised from mice, digested and cultured in our microchambers. The 
data comparing responses of GDC-0941 sensitive and resistant bladder cancers in microchambers is presented in 
Fig. 3C. These data show that, as expected, a decrease in size of sensitive BL0269 tumors was significantly greater 
than in resistant tumors when exposed to GDC-0941 (Fig. 3C). However, even the so-called GDC-0941-resistant 
cell culture still responded to GDC-0941 treatment, suggesting that some GDC-0941-sensitive cells survived 
GDC-0941 treatment in mice and repopulated during the initial microchamber culture before GDC-0941 
treatment.
It should be noted that while MTT assay and Live/Dead staining were attempted as a means of evaluating 
cytotoxicity, these methodologies proved suboptimal for our purposes. MTT assay was challenging to normalize 
to the actual number of cells being exposed to drugs while dyes used for Live/Dead staining had limited perme-
ability into ellipsoids being culture in our device. Therefore, susceptibility to drugs was assessed by measuring 
ellipsoid diameters in the x-y plane and monitoring change in ellipsoid volume over time. The diameter in z-axis 
was assumed to be equal to the height of the cell culture chamber – 75 µm. Changes in tumor volume are com-
monly used for both in vitro and in vivo assessment of responses to chemotherapy16,32.
Cancer relapse in microchambers. Multiple studies have highlighted the importance of investigating 
relapse and heterogeneity of drug responses within cancer tissue39,40. A cancer model most commonly used for 
drug screening involves imbedding spheroids into Matrigel. This system helps fix spheroids spatially within the 
culture dish and allows one to characterize the growth of the same set of spheroids in response to anti-cancer 
drugs. While useful, such an approach has limitations. First, it is difficult to wash out dead cells from spheroids 
imbedded in Matrigel, meaning that the response to drugs is gauged by the rate of growth, the more aggressive 
the drug the smaller the rate. This makes it difficult to study slow growing cancers, including a number of pri-
mary cancers. Second, because dead cells remain associated with spheroids inside Matrigel, it is difficult to model 
relapse – a process where tumor grows back after withdrawal of anti-cancer drugs.
In contrast, ellipsoids in microchambers shrink and expand easily in response to presence or absence of 
anti-cancer drugs, making this system well suited for drug response and relapse studies. This point is illustrated 
by images in Fig. 4A which shows changes in BL0269 ellipsoid size in response to introduction and withdrawal 
of PIK3 inhibitor (GDC-0941). The BL0269 ellipsoids were first exposed to GDC-0941 for six days, followed by 
Figure 2. Cancer dormancy in microchambers. (A) Cartoon describing that oxygenation of ellipsoids is 
uniform regardless of xy dimensions. (B) Numerical simulation of oxygen tension at the center of cancer 
ellipsoids with various dimeters (xy plane) in microchambers vs. cancer spheroids in suspension culture 
following 12 hr of incubation. (C) Ki67 staining profile for large and small ellipsoids cultured for 16 days in 
microchambers. Scale bars 100 μm.
www.nature.com/scientificreports/
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eight days of recovery period in which they were bathed in standard culture media. As shown in Fig. 4A, although 
initial drug treatment significantly shrunk ellipsoids, cancer cells repopulated the clumps after drug withdrawal.
In a clinical setting, cancer cells collected from the same tumor frequently exhibit heterogeneity in drug sus-
ceptibility. Analysis of 13 ellipsoids derived from the same PDX tissue and cultured in microchambers during 
exposure to GDC-0941 revealed considerable heterogeneity (Fig. 4B). Some clumps responded and disappeared 
after 14 days of treatment while other cancer constructs shrunk only to half the size during the same time. The 
differences and heterogeneity in responses of 3D constructs obtained from the same cancer tissue points to the 
possibility of investigating tumor heterogeneity using our culture system.
Culturing primary bladder cancer cells in microchambers. Our ultimate goal is to establish primary 
cancer cell cultures for drug screening and tumor heterogeneity studies. As a step towards this goal, we carried 
out experiments with biopsies from three different bladder cancer patients – de-identified as BL0924, BL0929 
and BL0908. Cancer tissue was dissociated into multi-cellular clumps, followed by seeding into microchambers 
as discussed earlier in the paper. Figure 5A shows representative ellipsoids from all three patients after 10 days of 
culture in microchambers. Retention of epithelial phenotype was confirmed by immunostaining which revealed 
strong expression of pan-cytokeratin and localization of F-actin cell-cell junctions (Fig. 5B). Following ten days 
of culture, BL0924 ellipsoids were exposed to gemcitabine, cisplatin and/or GDC-0941. As shown in Fig. 5C, only 
Figure 3. Drug responses of PDX-derived ellipsoids cultured microchambers. (A) Bright field images of 
BL0269 ellipsoids in microchambers treated with cisplatin (10 μM), gemcitabine (10 μM) or GDC-0941(1 μM). 
Cancer ellipsoids were cultured for 10 days prior to drug exposure. (B) Response of BL0269 ellipsoids to 
cisplatin (10 μM), gemcitabine (10 μM), cisplatin & gemcitabine (10 μM each), GDC-0941(1 μM) or triple 
combination. Untreated cancer ellipsoids served as control. Data represent the average of relative growth ratio 
of 6 biological samples per group ± SD; *p < 0.01. (C) Responses of standard (GDC-0941 sensitive) and GDC-
0941 resistant ellipsoids to 1 μM GDC-0941. Data represent the average of relative growth ratio of 7 biological 
samples per group ± SD; NS = non-significant; *p < 0.01. Scale bars 100 μm.
www.nature.com/scientificreports/
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gemcitabine had a statistically significant effect on BL0924 ellipsoids compared to the control group. Neither cis-
platin alone or in combination with gemcitabine was more effective than gemcitabine alone. Interestingly, unlike 
BL0269 PDX cells discussed earlier, BL0924 ellipsoids did not respond to GDC-0941 – suggesting that these 
cancer cells do not rely on the PI3K pathway for survival.
Conclusions
In this study, we report for the first-time the culture of PDX-derived and primary bladder cancer cells in micro-
fluidic devices. Bladder cancer cells formed ellipsoid-like constructs that exhibited growth and well-differentiated 
epithelial phenotype over the course of 30 days inside microchambers. A significant emphasis of the study was 
on demonstrating that drug response patterns of bladder cancer ellipsoids in microchambers paralleled those 
of matched PDXs in mice. Testing of BL0269 PDX cells in vitro revealed similar responsiveness to a PI3K inhib-
itor drug and resistance to chemotherapeutics, cisplatin and gemcitabine, as observed in vivo. Furthermore, 
PI3K-resistant subclones identified in PDX mice remained relatively resistant in microfluidic chambers.
Our method of 3D cancer cell culture has several advantages over other 3D culture approaches reported to 
date. 3D cell constructs cultured in our devices reach millimeter-scale xy dimensions without developing necrotic 
core – an issue that plagues standard cancer spheroid cultures21,41. This is due to the fact that oxygenation is uni-
form regardless of the tumor size in our microfluidic devices, and that ellipsoids receive sufficient nutrient levels.
3D constructs in our system are lodged between the floor and the roof of microchambers and are bathed in 
media. This ensures that dead cells are removed and tumors shrink upon drug exposure. In contrast, a standard 
way of embedding spheroids in Matrigel does not allow for removal of dead cells and therefore drug effects are 
gauged by the lack of growth and may be confounded by the dead cells attached to the tumor mass. This standard 
approach makes it difficult to study drug responsiveness of slow growing tumors whereas our method of moni-
toring shrinkage (or increase) in tumor size is well suited for this.
Furthermore, we made an interesting observation that location of proliferating cells within tumors in micro-
chambers varied based on the tumor size. Previous studies attributed the presence of proliferating cells at the 
tumor’s edge and dormant cells in the tumor’s core to gradients in oxygen42,43]. Our culture system provides uni-
form oxygenation of 3D cancer constructs regardless of lateral dimensions and points to alternative mechanisms 
for cancer dormancy.
Figure 4. Tumor relapse and heterogeneity studies in microchambers. (A) Brightfield images and growth curve 
of BL0269 ellipsoids in microchambers treated with GDC-0941 from day 10 to 16 followed by eight days of 
drug withdrawal. Data represent the average of relative growth ratio of 7 biological samples per group ± SD; 
*p < 0.01. Scale bars 100 μm. (B) Heterogeneity in responses of BL0269 ellipsoids to 1 μM GDC-0941. Top: 
images of resistant (S12) and sensitive (S9) ellipsoids (scale bars 100 μm). Drug treatment began after 10 days of 
culture and continued for 6 days. Bottom: changes in xy dimensions of 13 ellipsoids from the same BL0269 PDX 
mouse in response to 1 µM GDC-0941.
www.nature.com/scientificreports/
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The focus of this study was on demonstrating maintenance of primary cancer cells and retention of in vivo-like 
drug responses in simple microfluidic devices. The complexity of such devices may be enhanced in the future by 
placing multiple culture chambers on the same chip and by including drug reservoirs, gradient generators and 
valves to control sequence of delivery, temporal patterns and concentrations of drugs. Such a platform will be an 
important step towards personalizing cancer treatment.
Materials and Methods
Fabrication of microchambers. Microfluidic chambers were fabricated using basic soft lithography 
techniques described by us previously30. Briefly, a master mold was fabricated using a photomask (AutoCAD/
Art Services) for pattering SU-8 (Microchem Corp) on a silicon wafer (University Wafer). Single layer of poly-
dimethylsiloxane (PDMS; Dow Corning) was made by pouring a mixture of 1:10 ratio of the curing agent to base 
onto the master mold. After a 30-min degassing step, PDMS was baked at 70 °C for 80 min. Solidified PDMS 
layer was removed from the master mold using No.11 scalpel blade after which inlet and outlets were created 
using a metal puncher. A PDMS layer was treated with corona discharge instrument and then irreversibly bound 
onto a glass slide (75 mm × 25 mm). We found it important to deconstruct microchambers for higher quality of 
immunostaining. To achieve this, we devised a reversible PDMS to glass bonding strategy by replacing the oxygen 
plasma treatment with 20 min baking at 70 °C. Microchambers were filled with deionized (DI) water and kept at 
48 h at 4 °C prior to cell culture. Glass cloning cylinders (10 mm, Fisher Scientific) served as media reservoirs and 
were attached onto inlet and outlet using PDMS mixture as glue (1:10 ratio of curing agent to base). Microfluidic 
device with dimensions of individual channels is shown in Figure S1.
Preparation of cancer spheroids from PDX and patient tumors. Bladder cancer patient derived 
xenografts (PDXs) were established in mice as described by us previously15. All animal protocols were approved 
by the UC Davis Institutional Animal Care and Use Committee (IACUC, Protocol No. 17794) and The Jackson 
Laboratory (JAX) IACUC (Protocol No. 12027). Collection of cancer tumor tissues and clinical information from 
patients was approved by the UC Davis Institutional Review Board (Protocol No. 218204). Written informed 
consent was obtained from all patients providing specimens and all experiments were performed in accordance 
to relevant guidelines and regulations.
Figure S2 displays schematic illustration of steps involved in preparation and formation of cancer sphe-
roids from bladder cancer specimens. Identical protocol was carried out for PDX and patient tumor tissues. 
Prior to enzymatic digestion, a solid tissue specimen was placed in a sterile 10 cm petri dish having HBSS 
(with Ca and Mg), and then fragmented into small pieces (~mm) using a sterile No. 11 scalpel blade. Small 
tissue fragments were then incubated with collagenase type I (Gibco) in 10 ml of HBSS (with Ca and Mg) 
with final concentration of 235 U/ml. Enzymatic digestion was carried out in a 37 °C bath/shaker (200 rpm) 
for 25 mins. To isolate cell clusters with sizes ranging from 40 μm to 180 μm, digested tissue fragments 
were first passed through a sterile 180 μm size nylon mesh (Milipore), then a 40 μm cell strainer (Fischer 
Scientific). Cell clusters remaining on the 40 μm cell strainer were washed once with fresh culture media and 
Figure 5. Phenotype and drug responses of primary bladder cancer cells in microchambers. (A) Representative 
images of ellipsoids from 3 different patients at day 10 in culture. (B) F-actin and cytokeratin staining in a 
representative primary cancer ellipsoid (BL0908) at day10 in microchambers. Nuclei are stained with DAPI 
(Blue). (C) Responses of BL0924 ellipsoids to cisplatin, gemcitabine, cisplatin & gemcitabine and GDC-0941. 
Untreated BL0924 served as control. Data represent the average of 7 biological samples per group ± SD; 
*p < 0.01, NS = non-significant. Scale bars 100 μm.
www.nature.com/scientificreports/
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dispensed in a standard 6-well plate. Remaining tissue fragments on the 180 μm net filter were disaggregated 
and digested for additional 30 mins. Digestion and filtration steps were repeated up to three times to collect 
sufficient number of cell clusters. Following an overnight incubation, isolated cell clusters spontaneously 
began to form spherical structures as previously reported by Kondo et al. for colorectal cancer tissues16. To 
ensure completion of cell clusters transformation into spheroids, suspension culture in a 6-well plate con-
tinued for 48–72 h following digestion.
Cancer spheroids derived from bladder cancer PDXs were maintained in RPMI (Gibco) supplemented with 
30% (vol/vol) FBS (Invitrogen) and 1% (vol/vol) penicillin-streptomycin (Invitrogen); while primary cancer sphe-
roids were cultured in RPMI (Gibco) with B27 (50X, Life Technology) and 1% (vol/vol) penicillin-streptomycin 
(Invitrogen) supplemented with bFGF (20 ng/ml, Invitrogen) and EGF (20 ng/ml, Invitrogen)44.
Cancer ellipsoid culture in microchambers. Microchambers were first sterilized by 30 min UV expo-
sure in the tissue culture hood, followed by coating with 0.25 mg/mL of poly-L-lysine (sigma) solution diluted 
in DI water for 1.5 h at 37 °C. Devices were then flushed with PBS, followed by RPMI-based culture media. After 
multi-cellular clumps of cancer cells have formed in suspension culture, they were collected and re-suspended 
in <500 μl of culture media. Spheroids suspension in 100 µl was introduced at the inlet of the microchamber and 
negative pressure was applied at the outlet using a syringe vacuum. Following introduction of desired number of 
spheroids in the cell culture chamber, flow was stopped and inlet and out reservoirs were filled with 250 μl of cul-
ture media (see Fig. 1A for example of a microchamber). The difference in surface tension between inlet and out-
let media reservoirs created a very slow back and forth flow (on the order of microliters per hour) that enhanced 
diffusion –dominated delivery of nutrients to cells. The flow pattern was described in greater detail elsewhere45. 
Dimensions of the microfluidic chamber are provided in Figure S1.
To determine growth dynamics of ellipsoids in microchambers, we measured radii in the x-y plane and 
assumed the radius in the z-direction to be 75 µm. Our seeding protocol was designed to lodge spheroids between 
the floor and the roof of the microfluidic chamber, justifying the assumption of spheroid height being equal to the 
height of the chamber. For growth dynamics study described in Fig. 1D we began monitoring ellipsoids on day 10 
and continued until day 30. Therefore, xy dimensions of ellipsoids determined on day 10 of seeding were used to 
normalize measurements of ellipsoids on later days.
Cancer spheroids culture in Matrigel. In some of the experiments cancer spheroids were embedded in 
Matrigel and maintained in standard 48-well plates using protocols described in the literature46. Briefly, tissue 
culture wells were incubated with ~80 μl of Matrigel (BD Biosciences) at 37 °C for 20 min. Following gelation, 
cancer spheroids suspended in culture media were mixed with fresh Matrigel at 2.5% final concentration and then 
dispensed on the Matrigel-coated well. Media was exchanged every 48 h by gently removing the media from the 
top and adding 250 μl fresh culture media with 2.5% Matrigel.
To determine growth dynamics, radius of spheroids was determined using microscopy at the initial time point 
and then was used for normalizing radius measurements on subsequent days. Matrigel embedded spheroids were 
assumed to grow uniformly in x-y-z direction.
Evaluation of drug responses of cancer cell cultures in microchambers. Changes in cancer ellip-
soids size in the xy-plane were used to determine drug response. Time-lapse bright field images were processed 
using ImageJ to calculate the changes in the area (xy-plane) occupied by each ellipsoid before and after drug treat-
ments. Utilizing “Macros” plugin, the threshold and other settings were kept the same for all processed images. 
Area of each ellipsoid in the xy-plane after drug treatment was divided by its initial measurement for calculating 
the relative growth ratio as a means of determining drug response.
Immunostaining. We modified a previously published protocol to achieve effective immunofluorescent 
staining of 3D cancer constructs47. Prior to fixation of cells, culture media was removed from microchambers 
and channels were washed twice with PBS. Ellipsoids in microfluidic devices were fixed and permeabilized simul-
taneously at 4 °C by exposure to 4% paraformaldehyde (Electron Microscopy Sciences) and 1% Triton X-100 
(Invitrogen) in PBS for 3 h. Using washing solution (0.1% Triton in PBS), samples were flushed three times and 
then blocked overnight with 3% BSA and 0.1% Triton in PBS solution at 4 °C. Prior to antibody staining, a PDMS 
microchamber were removed from atop of the ellipsoids and replaced with a clean cloning cylinder (10 mm 
diameter) which served as solution reservoir. This step was critical to ensure successful penetration of antibodies 
to the center of compact cancer ellipsoids. Samples were then incubated for 48 h at 4 °C with primary antibodies 
diluted in incubation solution (PBS with 1% BSA and 0.1% Triton X-100). A list of primary antibodies and their 
dilution information are provided in Table S2. Samples were washed 5 times and then exposed to secondary anti-
bodies diluted in incubation solution for 24 h at 4 °C. Excess secondary antibody solution was then removed by 
flushing with washing solution 5 times. Secondary antibodies used were: Alexa-546 donkey anti-rabbit (1:800) 
and Alexa-488 donkey anti-mouse (1:800). Cell nuclei and F-actin were stained by incubation with DAPI (1:900) 
and Alexa Fluor 647 Phalloidin (1:15, Cell Signaling) solution at room temperature for 1.5 h. DAPI and Phalloidin 
were both diluted in incubation solution. Afterwards samples were flushed 5 times with washing solution and 
incubated at 4 °C in PBS. Laser scanning confocal microscope (LSM700, Carl Zeiss, Jena, Germany) was used to 
image all samples.
Statistical analysis. Student t-test was used for statistical analysis. Minimum four biological duplicates were 
used for each condition and standard deviations were presented as error bars. Number of biological duplicates 
and p value threshold used for each experiment is listed in the figure captions.
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